Brief: Oragenics Enters Into Material Transfer Agreement With Biodextris For Mucosal Adjuvant For Intranasal COVID-19 Vaccine
Oragenics: Soars on adjuvant deal with Biodextris
Brief: Oragenics Announces Recent Capital Raise And Warrant Exercises Totaling $21.9 Million And The Redemption Of Its Series C Preferred Stock
Brief: SARS-CoV-2 Spike Protein Licensed By Oragenics From The NIH Demonstrates Protective Immunity In Mice
Brief: Oragenics Inc - Entered Into Sales Agreement For Offering Of Up To $20 Million Of Shares Of Common Stock
Brief: Oragenics Provides Update On Terra CoV-2 vaccine against SARS-CoV-2
U.S. STOCKS ON THE MOVE-Roku Inc, Oragenics Inc, Conagra Brands
Oragenics: Rises on adjuvant deal with Adjuvance Technologies
Brief: Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies For Covid-19 Vaccine Adjuvant
Brief: Oragenics Inc Announces $6.5 Mln Registered Direct Offer
Oragenics slumps on deep-discounted equity offering
Brief: Oragenics Prices $5.25 Million Common Stock Offering
Oragenics slumps on planned equity raise
Brief: Organics Announces Proposed Underwritten Public Offering
AMEX HALT EQUIPMENT CHANGEOVER LAST 0.49110
U.S. STOCKS ON THE MOVE-Facebook, Amazon.com, Nvidia
U.S. STOCKS ON THE MOVE-Norwegian Cruise Line, Charles Schwab, Social Capital Hedosophia, Farmmi
U.S. STOCKS ON THE MOVE-Conformis, Oragenics, Himax Technologies, Gamida Cell, Leaf Group
Oragenics: FDA 'agrees' with company's COVID-19 vaccine development approach